CoChat
Sign Up
Cited by 100Angiogenesis and VEGF in CancerIntraperitoneal and Appendiceal MalignanciesOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice

Hossein Pourgholami, Mohammad, Yan Cai, Zhao, Lu, Ying, Wang, Lisa, Lawson Morris, David·2006·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-05-1181
Open this paper in CoChat — free account

Abstract

Purpose: Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation. We have recently shown that albendazole inhibits peritoneal growth of human colorectal cancer cells (HT-29). The present study was designed to find out if albendazole can suppress ascites formation in ascites-producing peritoneal carcinomatosis. Experimental design: Female nude mice bearing peritoneal tumors of human ovarian cancer cells (OVCAR-3) were treated with albendazole. Following i.p. inoculation and ascites development, mice were given i.p. albendazole (150 mg/kg) or the vehicle × 3 weekly for 4 weeks. Results: Whereas vehicle-treated mice developed overt ascites requiring repeated aspiration, ascites formation in the albendazole-treated mice was markedly suppressed. As a result of this, 7 of 10 mice from the control group had to be euthanized before the course of treatment was over. Suppressed ascites production and reduced tumor vascularity observed was a result of dramatic reduction in tumor VEGF production as revealed by profoundly lower VEGF ascites fluid and plasma levels. In vitro, incubation of SKOV-3 cells with various concentrations of albendazole led to significant dose-dependent inhibition of VEGF secretion. Examination of floating tumor cells collected from the peritoneal wash revealed profound down-regulation of VEGF mRNA in albendazole-treated mice. Conclusions: These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-1181

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 49

  1. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000;5:45–50. · DOI
  2. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (Royal College of Radiologists) 2003;15:59–72. · DOI
  3. Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC. Inhibition of human ovarian cancer colony formation by Adriamycin and its major metabolites. Cancer Res 1980;40:4109–12.
  4. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506–16. · DOI
  5. Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002;62:2019–23.
  6. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004;64:7045–9. · DOI
  7. Liu J, Yang G, Thompson-Lanza, JA, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655–63. · DOI
  8. Johnston SRD. Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. Cancer Invest 2004;22:730–42. · DOI
  9. Willemse PH, de Vries EG. Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility? Drug Resist Update 2003;6:165–7. · DOI
  10. Mohamed F, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. J Surg Res 2003;113:114–20. · DOI
  11. Barrowman MM, Marriner SE, Bogan JA. The binding and subsequent inhibition of tubulin polymerization in Ascaris suum (in vitro) by benzimidazole anthelmintics. Biochem Pharmacol 1984;33:3037–40. · DOI
  12. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990;6:112–5. · DOI
  13. Morris DL, Dykes PW, Dickson B, Marriner SE, Bogan JA, Burrows FG. Albendazole in hydatid disease. BMJ 1983;286:103–4. · DOI
  14. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001;165:43–9. · DOI · Paper page
  15. Morris DL, Jourdan JL, Pourgholami MH. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 2001;61:42–6. · DOI · Paper page
  16. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002;8:2963–9.
  17. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002;1:1201–9.
  18. De Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs 1997;53:769–88. · DOI
  19. Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705–8. · DOI
  20. Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 2005;55:425–32. · DOI
  21. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880–6.
  22. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721–8.
  23. Hamilton TC, Young RC, Louie KG, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984;44:5286–90.
  24. Hamburger AW, Salmon SE, Kim MB, et al. Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 1978;38:3438–44.
  25. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087–92.
  26. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 2002;87:1182–7. · DOI
  27. Kobayashi H, Yagyu T, Inagaki K, et al. Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer. Int J Cancer 2004;110:134–9. · DOI
  28. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224–9.
  29. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991;51:2515–20.
  30. Pellizzaro C, Coradini D, Daidone MG. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 2002;23:735–40. · DOI
  31. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400. · DOI · Paper page
  32. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373–8. · DOI
  33. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364–8.
  34. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–5. · DOI
  35. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629–32.
  36. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360–8.
  37. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178–87. · DOI
  38. Mu J, Abe Y, Tsutsui T, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 1996;87:963–71. · DOI
  39. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998;58:2594–600.
  40. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161:1917–24. · DOI
  41. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–80. · DOI
  42. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76. · DOI · Paper page
  43. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998;58:1278–84.
  44. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747–57. · DOI
  45. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 1998;83:2528–33. · DOI
  46. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221–7. · DOI
  47. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39:1948–56. · DOI
  48. Mukhopadhyay D, Zeng H, Bhattacharya R. Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol Cell Biochem 2004;264:51–61. · DOI
  49. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249–56. · DOI

Cited by

Sorted by citations

Metadata

Authors
Hossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D.
Affiliations
  • Authors' Affiliation: Cancer Research Laboratories, Department of Surgery, St. George Hospital, University of New South Wales, Sydney, New South Wales, Australia
  • UNSW Sydney (AU)
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2006-03-15
Volume
12
Issue
6
Pages
1928-1935
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-05-1181
OpenAlex
W2115847666
Cited by
100
References
1
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 8 · 2020: 7 · 2019: 2 · 2018: 2 · 2017: 8 · 2016: 5 · 2015: 8 · 2014: 4 · 2013: 8 · 2012: 8
FWCI
1.90
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of New South Wales
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
albendazole, vascular endothelial growth factor, malignant ascites, ovarian cancer, peritoneal carcinomatosis, tumor angiogenesis, VEGF inhibition, OVCAR-3 cells, SKOV3 cells, nude mice
MeSH terms
Animals, Ascites, Female, Humans, Injections, Intraperitoneal, Mice, Inbred BALB C, Mice, Nude, Neovascularization, Pathologic, Ovarian Neoplasms, RNA, Messenger, Albendazole, Gene Expression, CA-125 Antigen, Protein Isoforms, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review